Ocugen (NASDAQ:OCGN) is a biopharmaceutical company focused on developing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. The company's diverse portfolio reflects its mission to address a broad spectrum of eye diseases with its breakthrough therapies. In the realm of vaccines, Ocugen has garnered attention for its partnership to develop Covaxin, a COVID-19 vaccine candidate, aimed at providing a solution for the global pandemic. The company is committed to innovative research and solutions that could potentially redefine treatments for patients worldwide. With an unwavering focus on addressing unmet medical needs, Ocugen's diverse project pipeline positions the company as a hopeful contender in the fight against both common and rare diseases.